MCID: AMY009
MIFTS: 50

Amyloidosis Aa

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Amyloidosis Aa

MalaCards integrated aliases for Amyloidosis Aa:

Name: Amyloidosis Aa 53
Aa Amyloidosis 53 59 29 72
Reactive Systemic Amyloidosis 72
Inflammatory Amyloidosis 59
Amyloid a Amyloidosis 53
Secondary Amyloidosis 59
Amyloidosis Secondary 55
Reactive Amyloidosis 59

Characteristics:

Orphanet epidemiological data:

59
aa amyloidosis
Inheritance: Multigenic/multifactorial;

Classifications:



External Ids:

ICD10 via Orphanet 34 E85.3
UMLS via Orphanet 73 C0221014
Orphanet 59 ORPHA85445
UMLS 72 C0221014 C3536715

Summaries for Amyloidosis Aa

NIH Rare Diseases : 53 Amyloidosis is a group of diseases in which a protein, called amyloid, builds up in the body's organs and tissues. Amyloidosis AA is also referred to as Secondary amyloidosis or Inflammatory amyloidosis. This disease is caused by a long-lasting infection or inflammatory disease such as rheumatoid arthritis, familial Mediterranean fever, or osteomyelitis. Infection or inflammation in the body causes an increased amount of a specific protein called serum amyloid A (SAA) protein. In this disease, part of the SAA protein forms deposits called "amyloid fibrils". These desposits occur in the space around the cells of certain tissues of the body. Amyloidosis AA usually begins as a disease in the kidneys, but other organs can be affected such as the liver and spleen. Medical or surgical treatment of the underlying infection or inflammatory disease can slow down or stop the progression of this condition.

MalaCards based summary : Amyloidosis Aa, also known as aa amyloidosis, is related to amyloidosis, hereditary, transthyretin-related and hyper-igd syndrome. An important gene associated with Amyloidosis Aa is SAA1 (Serum Amyloid A1), and among its related pathways/superpathways are Selenium Micronutrient Network and Statin Pathway. The drugs Colchicine and Tubulin Modulators have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and spleen, and related phenotypes are hypotension and proteinuria

Wikipedia : 75 AA amyloidosis is a form of amyloidosis, a disease characterized by the abnormal deposition of fibers of... more...

Related Diseases for Amyloidosis Aa

Diseases in the Amyloidosis family:

Al Amyloidosis Amyloidosis Aa
Hereditary Amyloidosis Primary Localized Amyloidosis
Ah Amyloidosis

Diseases related to Amyloidosis Aa via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 486, show less)
# Related Disease Score Top Affiliating Genes
1 amyloidosis, hereditary, transthyretin-related 32.5 TTR APOA1
2 hyper-igd syndrome 31.1 SAA1 CRP
3 muckle-wells syndrome 30.9 MEFV CRP
4 wells syndrome 30.9 MEFV CRP
5 cryopyrin-associated periodic syndrome 30.8 SAA4 CRP
6 al amyloidosis 30.6 TTR B2M
7 familial mediterranean fever 30.5 SAA4 SAA2 SAA1 MEFV CRP
8 relapsing fever 30.5 MEFV CRP
9 peritonitis 30.4 MEFV CRP B2M
10 hypersensitivity reaction type iii disease 30.4 MEFV CRP
11 polyarteritis nodosa 30.3 MEFV CRP
12 adult-onset still's disease 30.2 MEFV CRP
13 analbuminemia 30.2 TTR CRP
14 hypersensitivity vasculitis 30.1 MEFV CRP
15 coronary stenosis 29.7 CRP APOA1
16 hereditary amyloidosis 29.7 TTR B2M APOA1
17 amyloidosis 29.0 TTR SAA4 SAA2 SAA1 MEFV B2M
18 vascular disease 28.8 LPA CRP APOA1
19 kidney disease 28.6 TTR LPA LCAT CRP B2M
20 lipid metabolism disorder 28.5 LPA LCAT CRP APOA1
21 unicentric castleman disease 10.5 SAA4 CRP
22 bronchus cancer 10.5 SAA1 CRP
23 blepharochalasis 10.5 TTR SAA1
24 rheumatoid arthritis 10.5
25 wild type abeta2m amyloidosis 10.4
26 pericardium disease 10.4 MEFV CRP
27 arthritis 10.4
28 decubitus ulcer 10.4 TTR CRP
29 pharyngitis 10.4 MEFV CRP
30 spondyloarthropathy 1 10.4
31 inflammatory spondylopathy 10.4
32 glomerulonephritis 10.4
33 spondylitis 10.4
34 henoch-schoenlein purpura 10.3 MEFV CRP
35 periodic fever, familial, autosomal dominant 10.3
36 tarsal tunnel syndrome 10.3 TTR B2M
37 tibial neuropathy 10.3 TTR B2M
38 pyelitis 10.3 CRP B2M
39 median rhomboid glossitis 10.3 TTR B2M
40 renal tuberculosis 10.3 CRP B2M
41 amyloid tumor 10.3 TTR B2M
42 palindromic rheumatism 10.3 MEFV CRP
43 nerve compression syndrome 10.3 TTR B2M
44 juvenile rheumatoid arthritis 10.3
45 dysentery 10.3 TTR CRP
46 retinitis pigmentosa 7 10.3 TTR B2M
47 kwashiorkor 10.2 TTR LCAT
48 pleurisy 10.2 MEFV CRP
49 psoriatic arthritis 10.2
50 rheumatic disease 10.2
51 arthropathy 10.2
52 brucellosis 10.2 SAA1 MEFV CRP
53 apo a-i deficiency 10.2 LCAT APOA1
54 renal cell carcinoma, nonpapillary 10.2
55 systemic lupus erythematosus 10.2
56 autosomal recessive disease 10.2
57 lupus erythematosus 10.2
58 posttransplant acute limbic encephalitis 10.2
59 hereditary periodic fever syndrome 10.2
60 familial lcat deficiency 10.2 LCAT APOA1
61 pericarditis 10.2 MEFV CRP
62 hemorrhagic fever with renal syndrome 10.2 CRP B2M
63 fish-eye disease 10.1 LCAT APOA1
64 macroglossia 10.1
65 sarcoidosis 1 10.1
66 body mass index quantitative trait locus 11 10.1
67 body mass index quantitative trait locus 9 10.1
68 body mass index quantitative trait locus 8 10.1
69 body mass index quantitative trait locus 4 10.1
70 body mass index quantitative trait locus 10 10.1
71 body mass index quantitative trait locus 7 10.1
72 body mass index quantitative trait locus 12 10.1
73 body mass index quantitative trait locus 14 10.1
74 body mass index quantitative trait locus 18 10.1
75 body mass index quantitative trait locus 19 10.1
76 body mass index quantitative trait locus 20 10.1
77 hepatocellular adenoma 10.1
78 protein-losing enteropathy 10.1
79 erysipelas 10.1
80 goiter 10.1
81 histiocytosis 10.1
82 myopathy 10.1
83 prion disease 10.1
84 adenoma 10.1
85 bronchiectasis 10.1
86 splenomegaly 10.1
87 fetal macrosomia 10.1 LCAT APOA1
88 xanthogranulomatous pyelonephritis 10.1
89 pulmonary tuberculosis 10.1
90 heart conduction disease 10.1 TTR CRP
91 familial cold autoinflammatory syndrome 1 10.0
92 fibrosis of extraocular muscles, congenital, 1 10.0
93 myositis 10.0
94 cystic fibrosis 10.0
95 immune deficiency disease 10.0
96 langerhans cell histiocytosis 10.0
97 leptin deficiency or dysfunction 10.0
98 inflammatory bowel disease 10.0
99 crohn's colitis 10.0
100 lymphoproliferative syndrome 10.0
101 igg4-related disease 10.0
102 familial cold autoinflammatory syndrome 10.0
103 endocarditis 10.0
104 neutropenia 10.0
105 crescentic glomerulonephritis 10.0
106 gout 10.0
107 cholestasis 10.0
108 urticaria 10.0
109 hepatitis c 10.0
110 acute pancreatitis 10.0
111 membranoproliferative glomerulonephritis 10.0
112 acute kidney failure 10.0
113 purpura 10.0
114 intestinal pseudo-obstruction 10.0
115 pustulosis of palm and sole 10.0
116 congestive heart failure 10.0
117 chronic kidney disease 10.0
118 psoriasis 10.0
119 macroglobulinemia 10.0
120 diabetes mellitus 10.0
121 cholangitis 10.0
122 alopecia 10.0
123 cold urticaria 10.0
124 aneurysm 10.0
125 encephalopathy 10.0
126 autoinflammatory syndrome 10.0
127 testicular yolk sac tumor 10.0 TTR APOA1
128 carotenemia 10.0 TTR LPA
129 proteasome-associated autoinflammatory syndrome 1 10.0
130 acquired metabolic disease 9.9 TTR CRP APOA1
131 neurofibromatosis, type ii 9.9
132 paraplegia 9.9
133 achalasia 9.9
134 obstructive jaundice 9.9 TTR CRP
135 hyperalphalipoproteinemia 1 9.9 LCAT APOA1
136 aortic aneurysm, familial abdominal, 1 9.9
137 autoimmune disease 9.9
138 gastroesophageal reflux 9.9
139 colchicine resistance 9.9
140 creutzfeldt-jakob disease 9.9
141 familial mediterranean fever, autosomal dominant 9.9
142 felty syndrome 9.9
143 inclusion body myositis 9.9
144 cyclic neutropenia 9.9
145 osteoporosis 9.9
146 variegate porphyria 9.9
147 schistosoma mansoni infection, susceptibility/ 9.9
148 scleroderma, familial progressive 9.9
149 temporal arteritis 9.9
150 tracheopathia osteoplastica 9.9
151 celiac disease 1 9.9
152 epidermolysis bullosa dystrophica, autosomal recessive 9.9
153 lymphoma, hodgkin, classic 9.9
154 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
155 ciliary dyskinesia, primary, 1 9.9
156 myeloma, multiple 9.9
157 periodontitis, chronic 9.9
158 pituitary hormone deficiency, combined, 2 9.9
159 glanzmann thrombasthenia 9.9
160 tracheobronchomegaly 9.9
161 caroli disease, isolated 9.9
162 inflammatory bowel disease 2 9.9
163 branchiootic syndrome 1 9.9
164 gastrointestinal stromal tumor 9.9
165 kala-azar 1 9.9
166 leukemia, chronic myeloid 9.9
167 myocardial infarction 9.9
168 mevalonic aciduria 9.9
169 bone mineral density quantitative trait locus 8 9.9
170 microvascular complications of diabetes 3 9.9
171 microvascular complications of diabetes 4 9.9
172 microvascular complications of diabetes 6 9.9
173 microvascular complications of diabetes 7 9.9
174 bone mineral density quantitative trait locus 15 9.9
175 cholangitis, primary sclerosing 9.9
176 aspergillosis 9.9
177 human herpesvirus 8 9.9
178 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.9
179 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.9
180 pulmonary hypertension 9.9
181 kartagener syndrome 9.9
182 foodborne botulism 9.9
183 exanthem 9.9
184 hereditary lymphedema 9.9
185 small cell carcinoma 9.9
186 caroli disease 9.9
187 lymphoma 9.9
188 diffuse alopecia areata 9.9
189 colitis 9.9
190 ischemic colitis 9.9
191 left ventricular noncompaction 9.9
192 recessive dystrophic epidermolysis bullosa 9.9
193 polycystic kidney disease 9.9
194 multicentric castleman disease 9.9
195 castleman disease 9.9
196 osteomyelitis 9.9
197 bacterial infectious disease 9.9
198 interstitial nephritis 9.9
199 mastitis 9.9
200 renal hypertension 9.9
201 chronic pyelonephritis 9.9
202 portal hypertension 9.9
203 mesenteric lymphadenitis 9.9
204 spondyloarthropathy 9.9
205 pyelonephritis 9.9
206 mitral valve insufficiency 9.9
207 autonomic neuropathy 9.9
208 nephrotic syndrome 9.9
209 esophagitis 9.9
210 common variable immunodeficiency 9.9
211 posterior uveitis 9.9
212 uveitis 9.9
213 diarrhea 9.9
214 porphyria 9.9
215 beriberi 9.9
216 polyneuropathy 9.9
217 interstitial cystitis 9.9
218 schistosomiasis 9.9
219 toxic shock syndrome 9.9
220 sclerosing cholangitis 9.9
221 echinococcosis 9.9
222 nodular nonsuppurative panniculitis 9.9
223 panniculitis 9.9
224 rheumatic fever 9.9
225 thrombocytopenia 9.9
226 lymphadenitis 9.9
227 cystitis 9.9
228 duodenal ulcer 9.9
229 enthesopathy 9.9
230 hepatitis b 9.9
231 constipation 9.9
232 hepatitis 9.9
233 hidradenitis suppurativa 9.9
234 hidradenitis 9.9
235 macrocytic anemia 9.9
236 corneal dystrophy 9.9
237 epidermolysis bullosa 9.9
238 glycogen storage disease 9.9
239 endometriosis 9.9
240 cryoglobulinemia 9.9
241 churg-strauss syndrome 9.9
242 interstitial lung disease 9.9
243 cellulitis 9.9
244 aortic aneurysm 9.9
245 gastritis 9.9
246 gastrointestinal tuberculosis 9.9
247 pyoderma 9.9
248 schnitzler syndrome 9.9
249 clear cell renal cell carcinoma 9.9
250 uremia 9.9
251 epidermolysis bullosa dystrophica 9.9
252 elephantiasis 9.9
253 pancreatitis 9.9
254 aortitis 9.9
255 conjunctivitis 9.9
256 severe combined immunodeficiency 9.9
257 connective tissue disease 9.9
258 thyroiditis 9.9
259 monoclonal gammopathy of uncertain significance 9.9
260 diverticulitis 9.9
261 gastrointestinal system disease 9.9
262 end stage renal failure 9.9
263 periodontitis 9.9
264 intestinal obstruction 9.9
265 ileus 9.9
266 lung disease 9.9
267 herpes zoster 9.9
268 pyoderma gangrenosum 9.9
269 ulcerative colitis 9.9
270 vasculitis 9.9
271 neuropathy 9.9
272 crohn's disease 9.9
273 parasitic helminthiasis infectious disease 9.9
274 lattice corneal dystrophy 9.9
275 autosomal dominant polycystic kidney disease 9.9
276 leishmaniasis 9.9
277 visceral leishmaniasis 9.9
278 pulmonary embolism 9.9
279 diastolic heart failure 9.9
280 47,xyy 9.9
281 congenital hepatic fibrosis 9.9
282 hypertrophic cardiomyopathy 9.9
283 allergic angiitis 9.9
284 antisynthetase syndrome 9.9
285 cytokine deficiency 9.9
286 eosinophilic granulomatosis with polyangiitis 9.9
287 horseshoe kidney 9.9
288 lymphangiectasis 9.9
289 medullary sponge kidney 9.9
290 microscopic polyangiitis 9.9
291 mounier-kuhn syndrome 9.9
292 mycobacterium abscessus 9.9
293 pure autonomic failure 9.9
294 rheumatoid vasculitis 9.9
295 rosai-dorfman disease 9.9
296 small cell carcinoma of the bladder 9.9
297 spondylarthropathy 9.9
298 systemic onset juvenile idiopathic arthritis 9.9
299 thrombasthenia 9.9
300 back pain 9.9
301 dysautonomia 9.9
302 headache 9.9
303 aapoaii amyloidosis 9.9
304 primary lymphedema 9.9
305 acute liver failure 9.9
306 lymphedema 9.9
307 membranous nephropathy 9.9
308 mesangial proliferative glomerulonephritis 9.9
309 lipoprotein glomerulopathy 9.9 LPA LCAT
310 leukodystrophy, hypomyelinating, 3 9.8 LPA APOA1
311 alzheimer disease 9.8
312 mycobacterium tuberculosis 1 9.8
313 filariasis 9.8
314 lepromatous leprosy 9.8
315 sarcoma 9.8
316 pancytopenia 9.8
317 allergic bronchopulmonary aspergillosis 9.8
318 bronchiolitis 9.8
319 systemic scleroderma 9.8
320 spindle cell sarcoma 9.8
321 liver cirrhosis 9.8
322 septic arthritis 9.8
323 dysphagia 9.8
324 spinal cord injury 9.8
325 myelofibrosis 9.8
326 acute kidney tubular necrosis 9.8
327 sapho syndrome 9.8
328 primary hypertrophic osteoarthropathy 9.8
329 hypothyroidism 9.8
330 skin disease 9.8
331 erdheim-chester disease 9.8
332 proliferative glomerulonephritis 9.8
333 paralytic ileus 9.8
334 primary biliary cholangitis 9.8
335 prosthetic joint infection 9.8
336 hypobetalipoproteinemia, familial, 2 9.8 LPA APOA1
337 leprosy 3 9.7
338 hansen's disease 9.7
339 helix syndrome 9.7
340 poems syndrome 9.7
341 agammaglobulinemia 9.7
342 paresthesia 9.7
343 basement membrane disease 9.7
344 hyperlipoproteinemia, type iii 9.7 LPA APOA1
345 amyloidosis, finnish type 9.7
346 cardiac arrhythmia 9.7
347 multiple sclerosis 9.7
348 kaposi sarcoma 9.7
349 mesothelioma, malignant 9.7
350 phosphatase, acid, of tissues 9.7
351 down syndrome 9.7
352 alkaptonuria 9.7
353 chediak-higashi syndrome 9.7
354 eosinophilic fasciitis 9.7
355 factor x deficiency 9.7
356 glycogen storage disease ib 9.7
357 hemochromatosis, type 1 9.7
358 mycosis fungoides 9.7
359 adrenoleukodystrophy 9.7
360 kelley-seegmiller syndrome 9.7
361 ataxia and polyneuropathy, adult-onset 9.7
362 renal cell carcinoma, papillary, 1 9.7
363 complement component 5 deficiency 9.7
364 intraocular pressure quantitative trait locus 9.7
365 nephrotic syndrome, type 13 9.7
366 hydrops, lactic acidosis, and sideroblastic anemia 9.7
367 cryptogenic organizing pneumonia 9.7
368 hyperphosphatemia 9.7
369 abdominal tuberculosis 9.7
370 marginal zone b-cell lymphoma 9.7
371 atrioventricular block 9.7
372 ileitis 9.7
373 cardiac arrest 9.7
374 thrombosis 9.7
375 obstructive nephropathy 9.7
376 pelvic inflammatory disease 9.7
377 keratoconus 9.7
378 dermatomyositis 9.7
379 open-angle glaucoma 9.7
380 strongyloidiasis 9.7
381 anhidrosis 9.7
382 respiratory failure 9.7
383 disseminated intravascular coagulation 9.7
384 chondrocalcinosis 9.7
385 gastroparesis 9.7
386 allergic hypersensitivity disease 9.7
387 hemosiderosis 9.7
388 pulmonary alveolar proteinosis 9.7
389 leukemia 9.7
390 hepatic coma 9.7
391 acute leukemia 9.7
392 pyloric stenosis 9.7
393 blastomycosis 9.7
394 locked-in syndrome 9.7
395 leiomyoma 9.7
396 telangiectasis 9.7
397 quadriplegia 9.7
398 acute cystitis 9.7
399 intestinal tuberculosis 9.7
400 hepatic encephalopathy 9.7
401 azoospermia 9.7
402 skeletal tuberculosis 9.7
403 calcinosis 9.7
404 epilepsy 9.7
405 mononeuritis multiplex 9.7
406 leiomyosarcoma 9.7
407 myeloproliferative neoplasm 9.7
408 ankylosis 9.7
409 leptospirosis 9.7
410 basal cell carcinoma 9.7
411 kidney cancer 9.7
412 benign mesothelioma 9.7
413 bronchiolitis obliterans 9.7
414 anuria 9.7
415 iga glomerulonephritis 9.7
416 demyelinating disease 9.7
417 bone inflammation disease 9.7
418 systemic mastocytosis 9.7
419 mixed connective tissue disease 9.7
420 mastocytosis 9.7
421 plasmacytoma 9.7
422 porokeratosis 9.7
423 thrombophlebitis 9.7
424 adrenal carcinoma 9.7
425 restrictive cardiomyopathy 9.7
426 syphilis 9.7
427 hyperglycemia 9.7
428 subacute bacterial endocarditis 9.7
429 rapidly progressive glomerulonephritis 9.7
430 ureteral obstruction 9.7
431 intestinal disease 9.7
432 pneumonia 9.7
433 follicular dendritic cell sarcoma 9.7
434 progressive multifocal leukoencephalopathy 9.7
435 b-cell lymphoma 9.7
436 enterobiasis 9.7
437 active peptic ulcer disease 9.7
438 extrinsic allergic alveolitis 9.7
439 pellagra 9.7
440 collagen disease 9.7
441 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.7
442 parapsoriasis 9.7
443 amebiasis 9.7
444 exophthalmos 9.7
445 hypopituitarism 9.7
446 fatty liver disease 9.7
447 fasciitis 9.7
448 miliary tuberculosis 9.7
449 hypereosinophilic syndrome 9.7
450 adrenomyeloneuropathy 9.7
451 cardiac rupture 9.7
452 chromophil renal cell carcinoma 9.7
453 hypoadrenalism 9.7
454 hypoaldosteronism 9.7
455 light chain deposition disease 9.7
456 multifocal motor neuropathy 9.7
457 pellucid marginal degeneration 9.7
458 polymyositis 9.7
459 pulmonary hyalinizing granuloma 9.7
460 pustulosis palmaris et plantaris 9.7
461 autonomic dysfunction 9.7
462 refractory anemia with excess blasts in transformation 9.7
463 virus-associated trichodysplasia spinulosa 9.7
464 lichen amyloidosis 9.7
465 discoid lupus erythematosus 9.7
466 nodal marginal zone b-cell lymphoma 9.7
467 rare disease in surgical orthopedic 9.7
468 cardiogenic shock 9.7
469 overgrowth syndrome 9.7
470 undetermined colitis 9.7
471 carpal tunnel syndrome 9.6 TTR B2M
472 carotid artery disease 9.6 LPA CRP APOA1
473 peripheral vascular disease 9.6 LPA CRP APOA1
474 arteries, anomalies of 9.5 LPA CRP APOA1
475 atherosclerosis susceptibility 9.5 LPA CRP APOA1
476 coronary artery anomaly 9.5 LPA CRP APOA1
477 arteriosclerosis 9.5 LPA CRP APOA1
478 hypolipoproteinemia 9.4 LPA LCAT APOA1
479 niemann-pick disease, type b 9.4 LPA LCAT APOA1
480 arcus corneae 9.4 LPA LCAT APOA1
481 lecithin:cholesterol acyltransferase deficiency 9.4 LPA LCAT APOA1
482 tangier disease 9.4 LPA LCAT APOA1
483 familial hyperlipidemia 9.4 LPA LCAT APOA1
484 coronary heart disease 1 9.1 LPA LCAT CRP APOA1
485 diabetes mellitus, noninsulin-dependent 9.0 LPA LCAT CRP APOA1
486 amyloidosis, familial visceral 7.9 TTR SAA4 SAA2 SAA1 MEFV LPA

Graphical network of the top 20 diseases related to Amyloidosis Aa:



Diseases related to Amyloidosis Aa

Symptoms & Phenotypes for Amyloidosis Aa

Human phenotypes related to Amyloidosis Aa:

59 32 (showing 24, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotension 59 32 hallmark (90%) Very frequent (99-80%) HP:0002615
2 proteinuria 59 32 hallmark (90%) Very frequent (99-80%) HP:0000093
3 nephropathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0000112
4 renal amyloidosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001917
5 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
6 malabsorption 59 32 frequent (33%) Frequent (79-30%) HP:0002024
7 vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002013
8 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
9 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
10 nephrotic syndrome 59 32 frequent (33%) Frequent (79-30%) HP:0000100
11 cholestasis 59 32 frequent (33%) Frequent (79-30%) HP:0001396
12 chronic diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002028
13 enlarged kidney 59 32 frequent (33%) Frequent (79-30%) HP:0000105
14 nausea 59 32 frequent (33%) Frequent (79-30%) HP:0002018
15 chronic kidney disease 59 32 frequent (33%) Frequent (79-30%) HP:0012622
16 malnutrition 59 32 frequent (33%) Frequent (79-30%) HP:0004395
17 abnormal oral mucosa morphology 32 frequent (33%) HP:0011830
18 acute kidney injury 59 32 occasional (7.5%) Occasional (29-5%) HP:0001919
19 hypothyroidism 59 32 very rare (1%) Very rare (<4-1%) HP:0000821
20 abnormal heart morphology 59 32 very rare (1%) Very rare (<4-1%) HP:0001627
21 adrenal insufficiency 59 32 very rare (1%) Very rare (<4-1%) HP:0000846
22 abnormality of the kidney 59 Very frequent (99-80%)
23 abnormality of oral mucosa 59 Frequent (79-30%)
24 amyloidosis 59 Very frequent (99-80%)

MGI Mouse Phenotypes related to Amyloidosis Aa:

46 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.23 APOA1 B2M CRP CTSB LCAT MEFV

Drugs & Therapeutics for Amyloidosis Aa

Drugs for Amyloidosis Aa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 50, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colchicine Approved Phase 4 64-86-8 6167 2833
2 Tubulin Modulators Phase 4
3 Antimitotic Agents Phase 4
4 Antirheumatic Agents Phase 4
5
Creatine Approved, Investigational, Nutraceutical Phase 3 57-00-1 586
6 Interleukin 1 Receptor Antagonist Protein Phase 3
7
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
8
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
9
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
10
Gliclazide Approved Phase 2 21187-98-4 3475
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
13
Pomalidomide Approved Phase 1, Phase 2 19171-19-8
14 Antimalarials Phase 2
15 Antiparasitic Agents Phase 2
16 Antiprotozoal Agents Phase 2
17 Alkylating Agents Phase 2
18 Antineoplastic Agents, Alkylating Phase 2
19 Antibodies Phase 2
20 Antibodies, Monoclonal Phase 2
21 Immunoglobulins Phase 2
22 Anti-Bacterial Agents Phase 1, Phase 2
23 Anti-Infective Agents Phase 1, Phase 2
24 Hormone Antagonists Phase 1, Phase 2
25 Antiemetics Phase 1, Phase 2
26 Gastrointestinal Agents Phase 1, Phase 2
27 HIV Protease Inhibitors Phase 1, Phase 2
28
protease inhibitors Phase 1, Phase 2
29 Hormones Phase 1, Phase 2
30 Peripheral Nervous System Agents Phase 1, Phase 2
31 glucocorticoids Phase 1, Phase 2
32 Anti-Inflammatory Agents Phase 1, Phase 2
33 Antineoplastic Agents, Hormonal Phase 1, Phase 2
34 Immunosuppressive Agents Phase 1, Phase 2
35 Autonomic Agents Phase 1, Phase 2
36 BB 1101 Phase 1, Phase 2
37 Immunologic Factors Phase 1, Phase 2
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
39 Angiogenesis Inhibitors Phase 1, Phase 2
40 Angiogenesis Modulating Agents Phase 1, Phase 2
41
Ichthammol Approved Phase 1 8029-68-3
42 Daratumumab Approved Phase 1 945721-28-8
43
Ixazomib Approved, Investigational Phase 1 1072833-77-2
44
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
45
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
46 Neurotransmitter Agents Phase 1
47
Liposomal doxorubicin Phase 1 31703
48 Topoisomerase Inhibitors Phase 1
49 Antibiotics, Antitubercular Phase 1
50 Esorubicin Phase 1

Interventional clinical trials:

(showing 13, show less)
# Name Status NCT ID Phase Drugs
1 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial Completed NCT02602028 Phase 4 colchicine
2 A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
3 International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
4 A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Completed NCT01705756 Phase 3 Kineret
5 A Phase II Study of Doxycycline in Patients With Amyloidosis Completed NCT01677286 Phase 2 Doxycycline 100 mg po bid x 12 months
6 Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis Completed NCT01072773 Phase 2 bortezomib;cyclophosphamide;dexamethasone
7 A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis Recruiting NCT03499808 Phase 2
8 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis Active, not recruiting NCT01570387 Phase 1, Phase 2 Pomalidomide;Dexamethasone
9 A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis Recruiting NCT03283917 Phase 1 Dexamethasone;Ixazomib
10 Phase I Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL) Terminated NCT00030381 Phase 1 4'-iodo-4'-deoxydoxorubicin
11 Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level Unknown status NCT01168570
12 Recurrent AA Amyloidosis After Renal Transplantation: Effects on Allograft Survival Completed NCT02704065
13 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Completed NCT00933296

Search NIH Clinical Center for Amyloidosis Aa

Genetic Tests for Amyloidosis Aa

Genetic tests related to Amyloidosis Aa:

# Genetic test Affiliating Genes
1 Aa Amyloidosis 29

Anatomical Context for Amyloidosis Aa

MalaCards organs/tissues related to Amyloidosis Aa:

41
Kidney, Liver, Spleen, Heart, Lung, Bone, Skin

Publications for Amyloidosis Aa

Articles related to Amyloidosis Aa:

(showing 1114, show less)
# Title Authors PMID Year
1
Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. 9 38
16236134 2005
2
IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. 9 38
14733913 2004
3
Association of FMF-related (MEFV) point mutations with secondary and FMF amyloidosis. 9 38
15122067 2004
4
A novel single-nucleotide polymorphism at the 5'-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. 9 38
11407685 2001
5
Comments on the letter of Galland et al. on "A rare cause of AA amyloidosis and end-stage kidney failure". 38
31119392 2019
6
A rare cause of AA amyloidosis and end-stage kidney failure: Questions. 38
30456663 2019
7
A rare cause of AA amyloidosis and end-stage kidney failure: Answers. 38
30456664 2019
8
Comments on Tașdemir et al.: A rare cause of AA amyloidosis and end-stage kidney failure. 38
31134325 2019
9
Modelling disease risk for amyloid A (AA) amyloidosis in non-human primates using machine learning. 38
31210531 2019
10
Mucocutaneous manifestations in systemic amyloidosis A retrospective analytical study in a tertiary care center. 38
30941743 2019
11
Morphological and primary structural consistency of fibrils from different AA patients (common variant). 38
31240945 2019
12
A case of protein-losing gastroenteropathy caused by systemic AA amyloidosis secondary to undifferentiated carcinoma of unknown primary origin. 38
31398725 2019
13
Specific changes in faecal microbiota are associated with familial Mediterranean fever. 38
31377728 2019
14
British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. 38
31384939 2019
15
Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review. 38
31364863 2019
16
Schnitzler syndrome. 38
31165908 2019
17
Cancer-Associated AA Amyloidosis Presenting as Crescentic Glomerulonephritis. 38
31194182 2019
18
Experimental model of oral transmissible AA amyloidosis in quails. 38
31199679 2019
19
Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review. 38
30772614 2019
20
Assessment of Mean Platelet Volume in Patients with AA Amyloidosis and AA Amyloidosis Secondary to Familial Mediterranean Fever: A Retrospective Chart - Review Study. 38
31123243 2019
21
Rheumatoid arthritis revealed by polyadenopathy, diarrhea and digestive AA amyloidosis. 38
30081199 2019
22
Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. 38
30535829 2019
23
Amyloid A amyloidosis secondary to avian tuberculosis in naturally infected domestic pekin ducks (Anas platyrhynchos domestica). 38
30961809 2019
24
Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids. 38
30846696 2019
25
Cell assay for the identification of amyloid inhibitors in systemic AA amyloidosis. 38
30739503 2019
26
Lipid membranes accelerate amyloid formation in the mouse model of AA amyloidosis. 38
30929476 2019
27
AA amyloidosis - Benefits and prospects of IL-6 inhibitors. 38
30132351 2019
28
Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. 38
29578360 2019
29
An Unusual Case of Acute Cholecystitis with Amyloidosis: A Case Report and Literature Review. 38
30449804 2019
30
Pulmonary Mycobacterium abscessus Infection with Reactive AA Amyloidosis: A Case Report and Brief Review of the Literature. 38
30333399 2019
31
[Schnitzler syndrome]. 38
30666414 2019
32
An automated microliter-scale high-throughput screening system (MSHTS) for real-time monitoring of protein aggregation using quantum-dot nanoprobes. 38
30796247 2019
33
Familial Mediterranean Fever. 38
30686512 2019
34
Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease. 38
31057541 2019
35
Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans. 38
31205631 2019
36
Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure. 38
31007959 2019
37
Systemic Amyloidosis with Renal Failure: A Challenging Diagnosis of SAPHO Syndrome. 38
31139585 2019
38
[Renal amyloidosis complicating adult onset Still's disease: about three cases]. 38
31303928 2019
39
Synchronous Unicentric Castleman Disease and Inflammatory Hepatocellular Adenoma: a Case Report. 38
31113603 2019
40
Secondary amyloidosis associated with heroin use and recurrent infections - A case report. 38
30581568 2019
41
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. 38
30612580 2019
42
[Prenatal care in patients with renal disease]. 38
30602185 2019
43
Ocular leptospiral infection leads to ciliary induction and local AA-amyloidosis in horses. 38
31343336 2019
44
Experimental transmission of AA amyloidosis in the European brown hare (Lepus europaeus) - first results. 38
31343351 2019
45
Significant association between renal function and area of amyloid deposition in kidney biopsy specimens from patients with AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis. 38
31343309 2019
46
Systemic AA amyloidosis secondary to rheumatoid arthritis may be treatable but is still difficult to manage in daily clinical practice. 38
31343283 2019
47
Is there a connection between the microbiome and AA amyloidosis? First hints from the European brown hare (Lepus europaeus). 38
31343352 2019
48
Value of natriuretic peptides and tissue Doppler imaging in the estimation of left ventricular filling pressure in patients with cardiac amyloidosis. 38
31217996 2019
49
Intestinal involvement in amyloidosis is a sequential process. 38
30230124 2018
50
AA amyloidosis associated with morbid obesity (clinical case). 38
30527964 2018
51
First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. 38
30101921 2018
52
Synchronous Unicentric Castleman Disease and Inflammatory Hepatocellular Adenoma: a Case Report. 38
30596615 2018
53
Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. 38
30071938 2018
54
[Renal amyloidosis revealing a cryopyrin associated periodic syndrome]. 38
30236822 2018
55
Familial Mediterranean fever in Chinese adult patients. 38
30085313 2018
56
Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis. 38
30400666 2018
57
Secondary, AA, Amyloidosis. 38
30274625 2018
58
Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs. 38
29697879 2018
59
Sickle cell disease: a case report of renal amyloidosis. 38
30305036 2018
60
AL amyloidosis: advances in diagnostics and treatment. 38
30299492 2018
61
Clinical and laboratory profile of renal amyloidosis: A single-center experience. 38
30381502 2018
62
[Schnitzler syndrome]. 38
30167710 2018
63
Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. 38
30231230 2018
64
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
. 38
29701172 2018
65
Renal sarcoidosis: approach to diagnosis and management. 38
29965860 2018
66
Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. 38
29767440 2018
67
Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. 38
29981275 2018
68
Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis. 38
29372474 2018
69
Heroin Use Is Associated with AA-Type Kidney Amyloidosis in the Pacific Northwest. 38
29907621 2018
70
OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. 38
29068915 2018
71
Kidney Transplant Recipients With Rheumatic Diseases: Epidemiological Data From the Polish Transplant Registries 1998-2015. 38
30056876 2018
72
Familial Mediterranean fever: overview of pathogenesis, clinical features and management. 38
30938266 2018
73
Profile of renal AA amyloidosis in older and younger individuals: a single-centre experience. 38
29775082 2018
74
Pathology and diagnosis of renal non-AL amyloidosis. 38
28828707 2018
75
'Care and Prevent': rationale for investigating skin and soft tissue infections and AA amyloidosis among people who inject drugs in London. 38
29739408 2018
76
Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature. 38
29450850 2018
77
Gastroparesis in a Patient with Gastric AL Amyloidosis. 38
30022922 2018
78
Intravenous drug users who require dialysis: causes of renal failure and outcomes. 38
29644070 2018
79
[Cryopyrin-associated periodic syndromes]. 38
29111302 2018
80
Apolipoprotein A-II induces acute-phase response associated AA amyloidosis in mice through conformational changes of plasma lipoprotein structure. 38
29618729 2018
81
Inhibitory effect of propolis on the development of AA amyloidosis. 38
29749997 2018
82
Small Bowel Amyloidosis. 38
29582184 2018
83
Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation. 38
29166802 2018
84
Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. 38
29364741 2018
85
Complete remission of nephrotic syndrome secondary to amyloid a amyloidosis in patient with inactive Crohn's disease after treatment by infliximab. 38
29657220 2018
86
Efficacy of anakinra in a patient with systemic amyloidosis presenting as amyloidoma. 38
29239128 2018
87
Variation of amino acid sequences of serum amyloid a (SAA) and immunohistochemical analysis of amyloid a (AA) in Japanese domestic cats. 38
29199213 2018
88
Acceleration of amyloid fibril formation by carboxyl-terminal truncation of human serum amyloid A. 38
29288051 2018
89
Coexistance of Amyloidosis and Primary Sjögren's Syndrome: An Overview. 38
28049394 2018
90
Post mortem findings and their relation to AA amyloidosis in free-ranging Herring gulls (Larus argentatus). 38
29494674 2018
91
Cardiac disease in familial Mediterranean fever. 38
29051974 2018
92
[Renal involvement in amyloidosis and sarcoidosis]. 38
29359290 2018
93
Clinical outcomes and survival in AA amyloidosis patients. 38
29173691 2017
94
Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF. 38
29148404 2017
95
Novel evidences of atypical manifestations in cryopyrin-associated periodic syndromes. 38
28079503 2017
96
Diffuse Peritoneal and Bowel Wall Infiltration by Light Chain-AL Amyloidosis with Omental Calcification Mimicking Abdominal Carcinomatosis - An Elderly Female with Incidental Finding of Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS). 38
29176541 2017
97
Spontaneous, Experimentally Induced, and Transmissible AA Amyloidosis in Japanese Quail ( Coturnix japonica). 38
28812532 2017
98
Systemic AA amyloidosis in the red fox (Vulpes vulpes). 38
28791746 2017
99
Experimental induction of chicken amyloid A amyloidosis in white layer chickens by inoculation with inactivated vaccines. 38
28421832 2017
100
Familial Mediterranean Fever Is Associated With Increased Mortality After Kidney Transplantation-A 19 Years' Single Center Experience. 38
28926523 2017
101
Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants. 38
28229334 2017
102
Late ventricular potentials in familial Mediterranean fever with and without AA amyloidosis. 38
29164000 2017
103
Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. 38
28745926 2017
104
AA amyloidosis associated with recurrent infections in the hyperimmunoglobulin E syndrome. 38
28571953 2017
105
Isolated AA Amyloidosis of the Radial Nerve. 38
28391751 2017
106
Kidney biopsy in AA amyloidosis: impact of histopathology on prognosis. 38
28686525 2017
107
Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. 38
28686088 2017
108
Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. 38
28834898 2017
109
Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options. 38
28705053 2017
110
Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. 38
28743750 2017
111
Hemodynamic deterioration after aortic valve replacement in a patient with mixed systemic amyloidosis. 38
27491541 2017
112
Periodic fever syndromes. 38
29773275 2017
113
Cellular mechanism of fibril formation from serum amyloid A1 protein. 38
28637682 2017
114
Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis. 38
28611868 2017
115
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. 38
28536823 2017
116
Pleural effusion in AA amyloidosis - A rare involvement of a rare disease. 38
28427884 2017
117
Recurrent AA Amyloidosis Combined With Chronic Active Antibody-mediated Rejection After Kidney Transplantation. 38
28794296 2017
118
Influence of C-terminal truncation of murine Serum amyloid A on fibril structure. 38
28733641 2017
119
Hepatic AA amyloidosis in a cat: cytologic and histologic identification of AA amyloid in macrophages. 38
28519899 2017
120
Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis. 38
28613962 2017
121
[AA amyloidosis]. 38
28462876 2017
122
Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. 38
28544119 2017
123
Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis. 38
28553897 2017
124
Gout and AA Amyloidosis: A Case Report and Review of the Literature. 38
28538281 2017
125
Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. 38
28558744 2017
126
AA Amyloidosis and Atypical Familial Mediterranean Fever with Exon 2 and 3 Mutations. 38
28868300 2017
127
Canakinumab for the treatment of familial Mediterranean fever. 38
28362189 2017
128
Gastrointestinal Amyloidosis: Review of the Literature. 38
28611935 2017
129
Systemic amyloidosis: novel therapies and role of biomarkers. 38
27540044 2017
130
AA amyloidosis is an emerging cause of nephropathy in obese patients. 38
28214252 2017
131
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. 38
27116248 2017
132
Transbronchial biopsies safely diagnose amyloid lung disease. 38
28393574 2017
133
Prognostication of survival and progression to dialysis in AA amyloidosis. 38
28434292 2017
134
Amyloid A (AA) amyloidosis in CByB6 mice: a model to study gastrointestinal amyloidosis. 38
28434288 2017
135
Apolipoprotein A-II accelerates reactive AA amyloidosis. 38
28434311 2017
136
Seed-dependent templating of murine AA amyloidosis. 38
28434369 2017
137
Cell-to-cell transfer of SAA1 protein in a cell culture model of systemic AA amyloidosis. 38
28361953 2017
138
Association of hidradenitis suppurativa and familial Mediterranean fever: A case series of 6 patients. 38
27238193 2017
139
Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients. 38
27838405 2017
140
The M694I/M694I genotype: A genetic risk factor of AA-amyloidosis in a group of Algerian patients with familial Mediterranean fever. 38
27956278 2017
141
Two diseases one remedy? Systemic amyloidosis secondary to hidradenitis suppurativa: Treatment with infliximab. 38
27862787 2017
142
Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration. 38
27150194 2017
143
[A Case of Hemodialysis-Associated Pelvic Amyloidoma Mimicking Renal Cancer-Associated Etiology]. 38
28264538 2017
144
Late Diagnosis of E148Q Mutation-Positive Familial Mediterranean Fever in a Kidney Transplant Patient With Fever of Unknown Origin: A Case Report. 38
28260482 2017
145
[Giant cell aortitis complicated by AA amyloidosis diagnosed with imaging techniques: Report of a case]. 38
27241076 2017
146
AA Amyloidosis and IgG4-Related Disease. 38
28177871 2017
147
The Schnitzler syndrome: chronic urticaria in disguise: a single-centre report of 11 cases and a critical reappraisal of the literature. 38
27606610 2017
148
AA Amylodisis Associated with Jugular Paraganglioma as a Rare Cause of Chronic Diarrhea. 38
28848772 2017
149
Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. 38
27908297 2017
150
Reply to: Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Dinoia et al. 38
27908298 2017
151
Colchicine in Renal Medicine: New Virtues of an Ancient Friend. 38
27951538 2017
152
[A rare concurrence of polymyalgia rheumatica and AA-amyloidosis]. 38
28418359 2017
153
A Novel Method of DAPI Staining for Differential Diagnosis of Renal Amyloidosis. 38
28954985 2017
154
Identification of a Unique Amyloid Sequence in AA Amyloidosis of a Pig Associated With Streptococcus Suis Infection. 38
27520112 2017
155
Deposition, Clearance, and Reinduction of Amyloid A Amyloid in Interleukin 1 Receptor Antagonist Knockout Mice. 38
27565681 2017
156
[Autoinflammatory diseases and kidney involvement]. 38
28745684 2017
157
Effect of lipid environment on amyloid fibril formation of human serum amyloid A. 38
27865770 2017
158
The N-terminal region of serum amyloid A3 protein activates NF-κB and up-regulates MUC2 mucin mRNA expression in mouse colonic epithelial cells. 38
28738073 2017
159
Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience. 38
29163488 2017
160
Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa. 38
27791393 2016
161
Carbamylation of the amino-terminal residue (Gly1) of mouse serum amyloid A promotes amyloid formation in a cell culture model. 38
27800611 2016
162
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. 38
27213830 2016
163
Experimental transmission of systemic AA amyloidosis in autoimmune disease and type 2 diabetes mellitus model mice. 38
27321428 2016
164
Studies on the potential risk of amyloidosis from exposure to silk fibroin. 38
27869107 2016
165
Secondary bladder amyloidosis with familial Mediterranean fever in a living donor kidney transplant recipient: a case report. 38
27760547 2016
166
Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes. 38
27741127 2016
167
MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. 38
27791951 2016
168
Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens. 38
27221072 2016
169
First Case of TNF-Receptor-Associated Autoinflammatory Syndrome (TRAPS) in Bulgaria. 38
27760004 2016
170
Amyloidosis and Unexpected Death: A Review of Seven Cases. 38
31239927 2016
171
Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. 38
27470486 2016
172
Poster 438 Bamboo Cervical Spine and Neck Pain in a Patient with AA Amyloidosis: A Case Report. 38
27673186 2016
173
Longitudinal study of experimental induction of AA amyloidosis in mice seeded with homologous and heterologous AA fibrils. 38
27165856 2016
174
Is the presence of AA amyloidosis associated with impaired coronary flow reserve? 38
27282832 2016
175
Renal amyloid A amyloidosis as a complication of hidradenitis suppurativa. 38
27340120 2016
176
Comparative Analysis of Outcomes of Kidney Transplantation in Patients With AA Amyloidosis and Chronic Glomerulonephritis. 38
27569937 2016
177
A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. 38
27221456 2016
178
Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. 38
25619282 2016
179
Amyloidosis enhancing activity of bovine amyloid A fibrils in C3H/HeN mice and cynomolgus monkeys (Macaca fascicularis). 38
27072531 2016
180
Systemic Amyloid A Amyloidosis in Island Foxes (Urocyon littoralis): Severity and Risk Factors. 38
26419399 2016
181
Mutational Spectrum of the MEFV Gene in AA Amyloidosis Associated With Familial Mediterranean Fever. 38
27225717 2016
182
Natural history of mevalonate kinase deficiency: a literature review. 38
27142780 2016
183
Characteristics of AA amyloidosis patients in San Francisco. 38
26370715 2016
184
Severe hidradenitis suppurativa complicated by renal AA amyloidosis. 38
26206410 2016
185
Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. 38
26867784 2016
186
[Causes and treatment of systemic amyloidosis]. 38
26768274 2016
187
Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis. 38
26936002 2016
188
Serum Amyloid A Protein Concentration in Blood is Influenced by Genetic Differences in the Cheetah (Acinonyx jubatus). 38
26585380 2016
189
Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. 38
26986117 2016
190
Amyloid A amyloidosis secondary to hyper IgD syndrome and response to IL-1 blockage therapy. 38
26819362 2016
191
Persistence of renal function in a patient diagnosed with concurrent amyloid amyloidosis and immunoglobulin light chain amyloidosis. 38
30375826 2016
192
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. 38
27110096 2016
193
Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis. 38
27725536 2016
194
Detection of AA76, a Common Form of Amyloid A Protein, as a Way of Diagnosing AA Amyloidosis. 38
27098620 2016
195
Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. 38
26788465 2016
196
Amyloidosis in a Captive Zebra Finch (Taeniopygia guttata) Research Colony. 38
27298248 2016
197
The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice. 38
26701064 2016
198
[Pathological and clinical correlations in renal AA amyloidosis: A Moroccan series of 30 cases]. 38
26608566 2015
199
Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: An autopsy case. 38
26179325 2015
200
[Recurrent fevers in childhood]. 38
26549686 2015
201
Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar Mediterranean fever, with tocilizumab. 38
25572486 2015
202
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. 38
26120866 2015
203
Prevalence of amyloid deposition in mature healthy chickens in the flock that previously had outbreaks of vaccine-associated amyloidosis. 38
25985816 2015
204
[AA-type amyloidosis secondary to multidrug resistant pulmonary tuberculosis: implications for therapy]. 38
26198876 2015
205
[Amyloidosis complicating spondyloarthropathies: Study of 15 cases]. 38
25458509 2015
206
Animal models for prion-like diseases. 38
25907990 2015
207
Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. 38
25761640 2015
208
Systemic AA amyloidosis as a prion-like disorder. 38
25533533 2015
209
Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies. 38
25828388 2015
210
Retrobulbar blood flow and carotid intima-media thickness alteration may relate to subclinic atherosclerosis in patients with chronic inflammatory diseases. 38
26099292 2015
211
Renal biopsy in the elderly: a single-center experience. 38
26135198 2015
212
[Histological and immunohistochemical examinations in the diagnosis of hepatic amyloidosis]. 38
26485775 2015
213
Predictors of AA amyloidosis in familial Mediterranean fever. 38
25586652 2015
214
FMF Genotype-phenotype correlation in Iranian Azeri Turks: Association between M694V/R761H mutation and amyloidosis. 38
26351556 2015
215
Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. 38
24510061 2015
216
Long-term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice. 38
25736960 2015
217
Colchicine use in isolated renal AA amyloidosis. 38
25453598 2015
218
Structural studies of the C-terminal 19-peptide of serum amyloid A and its Pro → Ala variants interacting with human cystatin C. 38
25736604 2015
219
Experimental transmission of AA amyloidosis by injecting the AA amyloid protein into interleukin-1 receptor antagonist knockout (IL-1raKO) mice. 38
25391376 2015
220
A case of membranoproliferative glomerulonephritis and AA amyloidosis complicated with pulmonary nontuberculous mycobacterial infection. 38
28509264 2015
221
Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. 38
25628446 2015
222
[Systemic secondary AA amyloidosis]. 38
25023854 2015
223
Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats. 38
25422367 2015
224
Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. 38
25504961 2015
225
Risk factors for AA amyloidosis in Germany. 38
25376380 2015
226
Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. 38
25491492 2015
227
Secondary renal amyloidosis in a patient of pulmonary tuberculosis and common variable immunodeficiency. 38
28197481 2015
228
[Cardiac tamponade as first manifestation in Mediterranean fever with autosomal dominant form]. 38
24365392 2015
229
Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years. 38
26666616 2015
230
Breast pain in a patient on dialysis: a rare manifestation of calcific uraemic arteriolopathy. 38
25576525 2015
231
Unknown aspect of the old disease: does dyslipidemia in systemic AA amyloidosis differ from the dyslipidemia in primary glomerulonephritis? 38
26181645 2015
232
AA amyloidosis treated with tocilizumab: case series and updated literature review. 38
25585627 2015
233
[Amyloidosis and neurological disorders: Treatable amyloidosis]. 38
26458571 2015
234
Safety of Percutaneous Ultrasound-Guided Kidney Biopsy in Patients with AA Amyloidosis. 38
26227420 2015
235
The Hidden Cost of Untreated Paragangliomas of the Head and Neck: Systemic Reactive (AA) Amyloidosis. 38
25838953 2015
236
AA amyloidosis: pathogenesis and targeted therapy. 38
25387054 2015
237
[RHEUTMATIC MYALGIA COMPLICATED BY AA-AMYLOIDOSIS]. 38
27149814 2015
238
Effect of heating on the stability of amyloid A (AA) fibrils and the intra- and cross-species transmission of AA amyloidosis. 38
26588017 2015
239
Intrinsic Stability, Oligomerization, and Amyloidogenicity of HDL-Free Serum Amyloid A. 38
26149928 2015
240
Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART--a case series over 11 years in a cohort of 1,153 patients. 38
26023828 2015
241
Failure of heterogeneous amyloid-enhancing factor in geriatric squirrel monkeys (Saimiri boliviensis). 38
25041324 2014
242
Blood values of captive beira antelope (Dorcatragus megalotis) prior to and during an outbreak of fibrinous pleuropneumonia syndrome (FPPS). 38
25632657 2014
243
De novo amyloidosis in a renal transplant patient. 38
25174445 2014
244
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. 38
23965844 2014
245
Cystic fibrosis and AA amyloidosis: a survey in the French cystic fibrosis network. 38
25054230 2014
246
Massive proteinuria and acute glomerulonephritis picture in a patient with Familial Mediterranean fever and E148Q mutation. 38
25362225 2014
247
Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis. 38
28509209 2014
248
Chronic renal failure due to amyloid nephropathy caused by chronic infection after total hip replacement. 38
28509203 2014
249
Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. 38
24939945 2014
250
Renal parenchymal calcification secondary to systemic AA amyloidosis. 38
25878784 2014
251
[Amyloidoses]. 38
25510121 2014
252
Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation. 38
25102446 2014
253
Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. 38
25220180 2014
254
Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study. 38
24866208 2014
255
Novel styrylbenzene derivatives for detecting amyloid deposits. 38
24815035 2014
256
Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. 38
24878279 2014
257
Characterization of amyloid in equine recurrent uveitis as AA amyloid. 38
24975895 2014
258
Outcome of 121 patients with renal amyloid a amyloidosis. 38
25364365 2014
259
Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. 38
24959698 2014
260
Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining. 38
24792621 2014
261
[AA Amyloidosis]. 38
24998825 2014
262
Serum amyloid protein A concentration in cryopyrin-associated periodic syndromes patients treated with interleukin-1 beta antagonist. 38
25069027 2014
263
Gastrointestinal amyloidosis in Australian indigenous patients. 38
24946817 2014
264
Renal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus. 38
25337080 2014
265
Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. 38
28509249 2014
266
Pearls from the Third Israeli Conference on FMF, other autoinflammatory disorders and AA amyloidosis. 38
24979827 2014
267
Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. 38
24252016 2014
268
Multidisciplinary approach to the treatment of cardiac AA amyloidosis and aortic stenosis due to Castleman's disease: a hybrid therapy with tocilizumab and aortic valve replacement. 38
24681024 2014
269
Red cell distribution width and mean platelet volume in amyloidosis. 38
23076775 2014
270
Transmission of systemic AA amyloidosis in animals. 38
24280941 2014
271
AA amyloidosis-resistant CE/J mice have Saa1 and Saa2 genes that encode an identical SAA isoform. 38
24228751 2014
272
Pregnancy outcome of five patients with renal amyloidosis regarding familial Mediterranean fever. 38
24168456 2014
273
Amyloid A amyloidosis in a Japanese patient with familial Mediterranean fever associated with homozygosity for the pyrin variant M694I/M694I. 38
24593212 2014
274
AA amyloidosis as a complication of primary lymphedema. 38
23964754 2014
275
Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. 38
24446872 2014
276
Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer. 38
24406424 2014
277
[Case of acute necrotizing esophagitis associated with AA amyloidosis secondary to bronchiectasis]. 38
24500318 2014
278
Amyloid A amyloidosis with subcutaneous drug abuse. 38
25340157 2014
279
Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties. 38
24440699 2014
280
Renal amyloidosis in a patient with X-linked agammaglobulinemia (Bruton's disease) and bronchiectasis. 38
24292696 2014
281
Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. 38
24261770 2014
282
Accumulation and absorption of serum amyloid A and apolipoprotein E fragments in the course of AA amyloidosis: a study in a mouse model. 38
25117094 2014
283
Systemic AA amyloidosis: epidemiology, diagnosis, and management. 38
25378951 2014
284
Proteomic analysis of highly prevalent amyloid A amyloidosis endemic to endangered island foxes. 38
25429466 2014
285
Amyloid A amyloidosis: frequently neglected renal disease in injecting drug users. 38
24644540 2014
286
Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis. 38
25197587 2014
287
AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab. 38
24106820 2013
288
Decreasing incidence of AA amyloidosis in Spain. 38
24020894 2013
289
Decreasing incidence of AA amyloidosis in Spain. 38
24020924 2013
290
Variegate porphyria complicated by systemic AA amyloidosis: a case report. 38
24131077 2013
291
Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. 38
23928237 2013
292
Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition. 38
24106838 2013
293
[Non AA amyloidosis and sarcoidosis revealed by an aggressive angiomyxoma of the pelvis. Rare association]. 38
24458681 2013
294
Familial Mediterranean fever (FMF) with proteinuria: clinical features, histology, predictors, and prognosis in a cohort of 25 patients. 38
24128782 2013
295
Secondary amyloidosis in a patient carrying mutations in the familial Mediterranean fever (FMF) and tumour necrosis factor receptor-1 syndrome (TRAPS) genes. 38
24286006 2013
296
Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder. 38
24117178 2013
297
[Cardiac amyloidosis: a case series of 14 patients, description and prognosis]. 38
24090573 2013
298
Evaluation of the mean platelet volume in secondary amyloidosis due to familial Mediterranean fever. 38
23673449 2013
299
[Renal AA amyloidosis during Langerhans' cell histiocytosis: case report]. 38
24282006 2013
300
AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. 38
23664546 2013
301
Pathogenetic mechanisms of amyloid A amyloidosis. 38
23959890 2013
302
[Chronic inflammation and AA amyloidosis]. 38
24006165 2013
303
Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature. 38
24078992 2013
304
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. 38
23704299 2013
305
[Changing spectrum of renal disease in HIV infection]. 38
24022452 2013
306
Incidence and clinical outcome of renal amyloidosis: a retrospective study. 38
24029260 2013
307
A case report of AA amyloidosis associated with familial periodic fever syndrome diagnosed after kidney transplantation: never say never. 38
24034047 2013
308
Interaction of serum amyloid A with human cystatin C--assessment of amino acid residues crucial for hCC-SAA formation (part II). 38
23836469 2013
309
IL-1β biological treatment of familial Mediterranean fever. 38
23322405 2013
310
Gastrointestinal AA amyloidosis following allogeneic hematopoietic stem cell transplant in a patient with chronic myelogenous leukemia. 38
23163702 2013
311
Decreasing incidence of AA amyloidosis in Spain. 38
23683125 2013
312
AA amyloidosis in vaccinated growing chickens. 38
23570943 2013
313
Serum amyloid A  renal amyloidosis in a chronic subcutaneous ("skin popping") heroin user. 38
24475449 2013
314
The permanent improvement of proteinuria and renal failure with colchicine and enalapril in a leukemic patient with renal amyloidosis secondary to ankylosing spondylitis: a review of the literature. 38
22975660 2013
315
[Amyloidosis of the ureter arising secondarily to the systemic lupus erythematosus : a case report]. 38
23945324 2013
316
Renal amyloidosis in Behçet's disease: clinicopathologic features of 8 cases. 38
22961375 2013
317
Systemic AA amyloidosis as a unique manifestation of a combined mutation of TNFRSF1A and MEFV genes. 38
23461592 2013
318
Experimental induction and oral transmission of avian AA amyloidosis in vaccinated white hens. 38
23548152 2013
319
Inflammatory bowel disease and systemic AA amyloidosis. 38
23371008 2013
320
Transmission of AA amyloidosis may cause outbreaks of amyloid A amyloidosis in chickens. 38
23642208 2013
321
Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. 38
23707811 2013
322
Human SAA1-derived amyloid deposition in cell culture: a consistent model utilizing human peripheral blood mononuclear cells and serum-free medium. 38
23461622 2013
323
Clinical characteristics of the patients with systemic amyloidosis in 2000-2010. 38
23246354 2013
324
AA amyloidosis complicating the hereditary periodic fever syndromes. 38
23280696 2013
325
Diffuse lipomatosis of the thyroid with amyloid deposition. 38
23339824 2013
326
Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia. 38
23474147 2013
327
AA amyloid nephropathy with predominant vascular deposition in Crohn's disease. 38
23439243 2013
328
When first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: a correspondence. 38
23022420 2013
329
Control of AA amyloidosis complicating Crohn's disease: a clinico-pathological study. 38
23373823 2013
330
Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis. 38
22815005 2013
331
How nature preserves fetuses. 38
23237236 2013
332
A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5. 38
23327342 2013
333
[Retrospective analysis of 11 cases of respiratory amyloidosis]. 38
23537551 2013
334
[Cardiorenal links in systemic amyloidosis]. 38
23866599 2013
335
Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn's disease. 38
23994979 2013
336
Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. 38
23689541 2013
337
[Renal amyloidosis]. 38
23991559 2013
338
Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. 38
23299888 2013
339
Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. 38
24236094 2013
340
AA-amyloidosis in autosomal dominant polycystic kidney disease caused by chronic cyst infections lasting for 30 years. 38
23545677 2013
341
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 38
23480774 2013
342
Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome. 38
23650909 2013
343
Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease. 38
23472940 2013
344
Amyloidosis in a child with hyperimmunoglobulinemia D syndrome. 38
23314147 2013
345
Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literature. 38
24267036 2013
346
Renal transplantation in secondary amyloidosis associated with tuberculosis. 38
24455394 2013
347
Nephrotic Syndrome Associated with Lung Cancer: A Rare Case of Malignancy Associated with AA Amyloidosis. 38
24558629 2013
348
Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk. 38
23137073 2013
349
Renal involvement in AA amyloidosis: clinical outcomes and survival. 38
23548761 2013
350
[Familial Mediterranean fever: not to be missed]. 38
23635502 2013
351
Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. 38
23223242 2013
352
A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. 38
23750281 2013
353
Characterization of the oligomerization and aggregation of human Serum Amyloid A. 38
23750222 2013
354
Systemic AA amyloidosis in a patient with lung metastasis from renal cell carcinoma. 38
22928906 2012
355
AA Amyloidosis in a patient with glycogen storage disorder and progressive chronic kidney disease. 38
26069801 2012
356
Massive pleural effusion due to pleural AA amyloidosis. 38
23250505 2012
357
Hepatic amyloidosis: morphologic spectrum of histopathological changes in AA and nonAA amyloidosis. 38
23154038 2012
358
Amyloidosis in autoinflammatory syndromes. 38
22878269 2012
359
AA amyloidosis: Mount Sinai experience, 1997-2012. 38
23239212 2012
360
Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. 38
22879465 2012
361
Attempts at suppression of amyloidogenesis in a mouse model by a variety of anti-inflammatory agents. 38
22878271 2012
362
A case of AA amyloidosis of the bladder with interstitial cystitis. 38
22905727 2012
363
Renal AA-amyloidosis in intravenous drug users--a role for HIV-infection? 38
23171281 2012
364
Familial Mediterranean fever in Japan. 38
23111802 2012
365
Familial Mediterranean fever: new phenotypes. 38
22878273 2012
366
Alkaptonuria is a novel human secondary amyloidogenic disease. 38
22850426 2012
367
(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. 38
22806059 2012
368
Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis. 38
21947375 2012
369
'Silent' carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient. 38
21995303 2012
370
Renal amyloidosis due to familial mediterranean fever misdiagnosed. 38
23716950 2012
371
Rheumatic heart disease associated with secondary renal amyloidosis. 38
22967253 2012
372
AA-Amyloid is cleared by endogenous immunological mechanisms. 38
22900541 2012
373
Reactive amyloidosis complicated by end-stage renal disease 28 years after liquid silicone injection in the buttocks. 38
23035166 2012
374
Secondary amyloidosis in Indigenous Australians. 38
24020342 2012
375
Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. 38
22042488 2012
376
Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. 38
22654109 2012
377
[Amyloidosis in sub-Saharan Africa]. 38
23174270 2012
378
Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis. 38
22589255 2012
379
[A case of cardiac AA amyloidosis]. 38
22692837 2012
380
Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. 38
22551153 2012
381
[Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis]. 38
22647474 2012
382
Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. 38
21931121 2012
383
Amyloidosis. 38
22402917 2012
384
Infliximab in the treatment of amyloidosis secondary to Crohn's disease. 38
22592423 2012
385
AA amyloidosis in the renal allograft: a report of two cases and review of the literature. 38
22833808 2012
386
[AA amyloidosis with cutaneous manifestations. Report of one case]. 38
22854696 2012
387
Association between clinical parameters and amyloid-positive area in gastroduodenal biopsy in reactive amyloidosis associated with rheumatoid arthritis. 38
21240500 2012
388
Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation. 38
22448726 2012
389
Setting up TRAPS. 38
21284532 2012
390
Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. 38
22260742 2012
391
The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients. 38
22320202 2012
392
Idiopathic systemic AA-amyloidosis in a skunk (Mephitis mephitis). 38
22448530 2012
393
Atypical AA amyloid deposits in bovine AA amyloidosis. 38
22149364 2012
394
Duodenal biopsy for diagnosis of renal involvement in amyloidosis. 38
22257541 2012
395
Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. 38
21771754 2012
396
AA-amyloidosis in a kidney biopsy on top of pauci-immune crescentic glomerulonephritis. 38
26069756 2012
397
Effects of AA amyloidosis on survival in peritoneal dialysis. 38
23147073 2012
398
Churg-Strauss syndrome associated with AA amyloidosis: a case report. 38
22891088 2012
399
Unusual renal manifestation of Caroli disease: AA amyloidosis. 38
22681158 2012
400
[Etiologic profile of amyloidosis of the elderly in Tunisia]. 38
22311442 2012
401
Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis. 38
22253527 2012
402
[Muckle-Wells syndrome caused by a new cryopyrin mutation: effective treatment with interleukin-1 antagonist]. 38
22997920 2012
403
A rare cause of secondary amyloidosis: common variable immunodeficiency disease. 38
24558615 2012
404
Amyloidosis of seminal vesicles; incidence and pathologic characteristics. 38
22207431 2012
405
AA amyloidosis: basic knowledge, unmet needs and future treatments. 38
22653707 2012
406
Relationship between amyloid deposition and intracellular structural changes in familial amyloidotic polyneuropathy. 38
21777941 2012
407
Systemic AA amyloidosis. 38
23225016 2012
408
Renal AA amyloidosis in a Castleman's disease patient. 38
23013971 2012
409
Review of eprodisate for the treatment of renal disease in AA amyloidosis. 38
22427728 2012
410
AA amyloid quantification in biopsy samples from the stomach. 38
22371903 2012
411
SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies. 38
21958847 2012
412
Cheetahs have 4 serum amyloid a genes evolved through repeated duplication events. 38
21987659 2012
413
Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases. 38
22808071 2012
414
Signs of cross-seeding: aortic medin amyloid as a trigger for protein AA deposition. 38
22070546 2011
415
Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1β-monoclonal antibody. 38
25984207 2011
416
Abnormal heart rate variability in AA amyloidosis of familial Mediterranean fever. 38
22080764 2011
417
Fatal gastrointestinal hemorrhage in a paraplegic man with undiagnosed AA (secondary) amyloidosis. 38
22014073 2011
418
Renal transplantation in AA amyloidosis associated with Whipple's disease. 38
21995309 2011
419
Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. 38
21992511 2011
420
[Use of etanercept in amyloidosis secondary to rheumatoid arthritis, a report of two cases]. 38
22078699 2011
421
Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. 38
21714848 2011
422
Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. 38
21844139 2011
423
Inflammation protein SAA2.2 spontaneously forms marginally stable amyloid fibrils at physiological temperature. 38
21942925 2011
424
P-wave dispersion in systemic AA amyloidosis of familial Mediterranean fever. 38
21484223 2011
425
Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. 38
21627560 2011
426
Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. 38
22011672 2011
427
[Secondary (AA) renal/bone amyloidosis complicating rheumatoid arthritis]. 38
23126056 2011
428
Renal AA amyloidosis in a patient with hereditary complete complement C4 deficiency. 38
21912034 2011
429
Nephropathy in association with annular psoriasis. 38
22334979 2011
430
Colchicine-sensitive nephrotic syndrome due to AA amyloidosis. 38
21770831 2011
431
Pathogenesis of experimental amyloid protein A amyloidosis in sore hocks-affected rabbits. 38
21815744 2011
432
Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. 38
21830877 2011
433
Amyloidosis and respiratory tract involvement: report of two cases. 38
21970207 2011
434
Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. 38
21173015 2011
435
Endoscopic and histopathological features of gastrointestinal amyloidosis. 38
21954412 2011
436
In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. 38
21807994 2011
437
Renal and suprarenal insufficiency secondary to familial Mediterranean fever associated with amyloidosis: a case report. 38
21851607 2011
438
Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. 38
21571086 2011
439
AA amyloidosis associated with hepatitis B. 38
21543651 2011
440
Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. 38
25984151 2011
441
Recurrent AA amyloidosis in a kidney transplant. 38
21496981 2011
442
Systemic reactive (AA) amyloidosis in the course of common variable immunodeficiency. 38
21838492 2011
443
The changing face of AA amyloidosis: a single center experience. 38
21838497 2011
444
Inhibitory effects of anti-IL-1β antibody in murine AA amyloidosis mode. 38
21838425 2011
445
AA amyloidosis: potential therapy with antisense oligonucleotides. 38
21838487 2011
446
Serum amyloid A3 (SAA3), not SAA1 appears to be the major acute phase SAA isoform in the pig. 38
21439655 2011
447
[Systemic amyloidosis AA in a liver transplant recipient with biliary complications in the posttransplant period]. 38
20573359 2011
448
A case of systemic amyloidosis associated with cyclic neutropenia. 38
21161286 2011
449
AA amyloidosis in a patient with Langerhans cell histiocytosis. 38
25984125 2011
450
[Renal amyloidosis: uncommon complication of sickle cell disease]. 38
21695882 2011
451
Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. 38
20931272 2011
452
Recent insights into the pathogenesis of type AA amyloidosis. 38
21403980 2011
453
Renal involvement in Castleman disease. 38
20656751 2011
454
Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. 38
21269584 2011
455
A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept. 38
19820941 2011
456
An inconspicuous insect bite as the cause of sepsis in a patient treated with infliximab due to rheumatoid arthritis. 38
21444275 2011
457
Generation and characterization of anti-AA amyloid-specific monoclonal antibodies. 38
22566822 2011
458
[Current methods of systemic amyloidosis diagnosis and monitoring of its course]. 38
21961333 2011
459
[Protracted Febrile Myalgia Syndrome with Henoch-Schönlein Purpura: an atypical presentation of Familial Mediterranean Fever]. 38
21483284 2011
460
[Clinical aspects of Familial Mediterranean fever]. 38
22041422 2011
461
Familial mediterranean fever in an Iranian patient with behcet disease. 38
24551444 2011
462
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents. 38
21639824 2011
463
Antisynthetase syndrome without myositis secondary to AA amyloidosis: a non-described association. 38
21270928 2011
464
Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis. 38
21067952 2011
465
Fatal acute pancreatitis associated with reactive AA amyloidosis in rheumatoid arthritis with end-stage renal disease: a report of three cases. 38
21467708 2011
466
[Secondary (AA) amyloidosis in Crohn's disease]. 38
22359896 2011
467
The Schnitzler syndrome. 38
21143856 2010
468
Rapid development of renal failure secondary to AA-type amyloidosis in a patient with polymyalgia rheumatica. 38
20969738 2010
469
Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. 38
20609610 2010
470
Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab. 38
21175229 2010
471
Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. 38
20440529 2010
472
AA amyloidosis associated with macroglobulinemia. 38
20953745 2010
473
Prion-like aggregates: infectious agents in human disease. 38
20870462 2010
474
A case of primary immune deficiency presenting with nephrotic syndrome. 38
25984052 2010
475
Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. 38
20229259 2010
476
Transmission of circulating cell-free AA amyloid oligomers in exosomes vectors via a prion-like mechanism. 38
20807507 2010
477
Echocardiographic diagnosis of systemic AA amyloidosis presenting with acute liver failure. 38
20821940 2010
478
Rapidly progressive glomerulonephritis complicating primary AL amyloidosis and multiple myeloma. 38
20042399 2010
479
Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. 38
20546191 2010
480
Systemic amyloidosis: a challenge for the rheumatologist. 38
20531382 2010
481
Oral involvement in a case of AA amyloidosis: a case report. 38
20591157 2010
482
[Concomitant diagnosis of acute myeloid leukaemia and chronic lymphoproliferative disorder with AA amyloidosis as a final event]. 38
19766258 2010
483
Variable intrafamilial expressivity of the rare tumor necrosis factor-receptor associated periodic syndrome-associated mutation I170N that affects the TNFR1A cleavage site. 38
20169391 2010
484
A case of emphysematous pyelonephritis in a patient with rheumatoid arthritis taking corticosteroid and low-dose methotrexate. 38
20536605 2010
485
[AA amyloidosis complicating sarcoidosis: two cases and literature review]. 38
20381218 2010
486
The frequency of familial mediterranean Fever related amyloidosis in renal waiting list for transplantation. 38
25610112 2010
487
A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. 38
20367305 2010
488
[A systemic amyloidosis presenting as a tracheobronchial amyloidosis]. 38
20219273 2010
489
[Peritoneal AA amyloidosis simulating peritoneal carcinomatosis: a case report]. 38
20188389 2010
490
Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. 38
20391474 2010
491
Coexistence of medullary sponge kidney and renal AA amyloidosis in a patient with nephrotic range proteinuria. 38
20355355 2010
492
AA-type amyloidosis in association with non-Hodgkin's lymphoma following CMV viremia: Autopsy case. 38
20403049 2010
493
[Interpretation of elevated serum troponin levels in end stage renal disease - case 2/2010]. 38
20127607 2010
494
Clinical and pathological features of renal amyloidosis: an analysis of 32 patients in a single Chinese centre. 38
20377777 2010
495
[Acute kidney transplant failure from de novo AA amyloidosis in a patient with pyoderma gangrenosum]. 38
20651898 2010
496
[Left ventricular noncompaction concurrent with bronchoectatic disease complicated by secondary AA-amyloidosis with renal involvement]. 38
20364708 2010
497
Restrictive cardiomyopathy in inherited ATTR amyloidosis (TTR-Ser23Asn) in a patient of German-Italian extraction. 38
22400056 2010
498
Systemic amyloidosis presenting as chronic diarrhea in a patient with ankylosing spondylitis. 38
20051751 2010
499
Obstructive nephropathy secondary to AA-type amyloidosis in ankylosing spondylitis. 38
20370461 2010
500
No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. 38
20091495 2010
501
Spontaneous resolution of multiple nodular pulmonary AA amyloidosis. 38
21048364 2010
502
[Amyloidosis in rheumatic diseases]. 38
21365934 2010
503
Isolation and characterization of monoclonal antibodies against bovine serum amyloid A1 protein. 38
19922333 2009
504
Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre. 38
19184513 2009
505
Differential affinity of serum amyloid A1 isotypes for high-density lipoprotein. 38
19922330 2009
506
Hereditary gelsolin amyloidosis mimicking Sjögren's syndrome. 38
19701715 2009
507
Oto-Rhino-Laryngology (ORL) tumor presentation in a case of systemic AA amyloidosis. 38
19951642 2009
508
IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. 38
19556300 2009
509
[From hereditary recurrent fevers to autoinflammatory syndromes: the contribution of genetics]. 38
20669551 2009
510
Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. 38
19797512 2009
511
Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. 38
19790131 2009
512
Unusual combination of tracheobronchopathia osteochondroplastica and AA amyloidosis. 38
19881980 2009
513
Systemic amyloidosis and the gastrointestinal tract. 38
19724253 2009
514
Renal AA amyloidosis secondary to morbid obesity? 38
19825338 2009
515
[41-year old patient with obscure diarrhea]. 38
19533073 2009
516
Renal amyloidosis in intravenous heroin addicts with nephrotic syndrome and renal failure. 38
19761730 2009
517
Clinical and genetic features of familial Mediterranean fever in Japan. 38
19531756 2009
518
AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. 38
19635871 2009
519
Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. 38
19393650 2009
520
Prevalence and origin of amyloid in kidney biopsies. 38
19561448 2009
521
Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. 38
19525413 2009
522
Unexpected remission of renal AA amyloidosis associated with rheumatoid arthritis. 38
19303340 2009
523
[Systemic amyloidoses in renal biopsy samples]. 38
19764159 2009
524
Current perspectives on familial Mediterranean fever. 38
19339884 2009
525
Fibrils from designed non-amyloid-related synthetic peptides induce AA-amyloidosis during inflammation in an animal model. 38
19582162 2009
526
[Amyloidoses in the Berlin Museum of Medical History of the Charité]. 38
19296111 2009
527
Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. 38
19366896 2009
528
[Amyloidosis in liver biopsies]. 38
19415368 2009
529
Familial Mediterranean Fever: a review for clinical management. 38
19091621 2009
530
[Diagnostics and therapy of AA amyloidosis]. 38
19333604 2009
531
Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. 38
19406970 2009
532
A case of systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. 38
19269784 2009
533
AA amyloidosis induced in sheep principally affects the gastrointestinal tract. 38
19217631 2009
534
Cathepsin D activity protects against development of type AA amyloid fibrils. 9
19740371 2009
535
[Familial Mediterranean fever as representative autoinflammatory disease]. 38
19489440 2009
536
Clinical features of familial Mediterranean fever: an Italian overview. 38
19530512 2009
537
Atraumatic splenic rupture in amyloidosis. 38
19291515 2009
538
Concomitant amyloidosis, renal papillary carcinoma and ipsilateral pelvicalyceal urothelial carcinoma in a patient with familial Mediterranean fever. 38
19291516 2009
539
Modern treatment of amyloidosis: unresolved questions. 38
19073820 2009
540
Slaughtered aged cattle might be one dietary source exhibiting amyloid enhancing factor activity. 38
19291511 2009
541
[A review for recent advances in AA amyloid research and therapeutic approach to AA amyloidosis complicating rheumatoid arthritis]. 38
19252376 2009
542
Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. 38
19033248 2009
543
Increasing fatal AA amyloidosis in hunting falcons and how to identify the risk: a report from the United Arab Emirates. 38
19657764 2009
544
[Fever from the cold--familial cold autoinflammatory syndrome]. 38
19385344 2009
545
Immunotargeting of apolipoprotein E in amyloid: an initial trial in mice. 38
19429798 2009
546
AA amyloidosis associated with a mutated serum amyloid A4 protein. 38
20536400 2009
547
Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice. 38
19149411 2008
548
Renal Behçet's disease: an update. 38
18221990 2008
549
Glomerular crescent formation in renal amyloidosis. A clinicopathological study and demonstration of upregulated cell-mediated immunity. 38
19049702 2008
550
[Systemic AA amyloidosis caused by familial Mediterranean fever and response to colchicine]. 38
19209520 2008
551
Review. Reflections on amyloidosis in Papua New Guinea. 38
18849285 2008
552
MEFV mutations in Japanese rheumatoid arthritis patients. 38
19210876 2008
553
Auto-inflammatory syndromes and oral health. 38
19193198 2008
554
Intermittent chronic neutropenia in a patient with familial Mediterranean fever. 38
18661496 2008
555
[Persistent diarrhoea, hypotension, polyneuropathy]. 38
19069686 2008
556
[Novel tool for diagnosis of amyloidosis]. 38
19086454 2008
557
Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. 38
18815155 2008
558
AA amyloidosis due to chronic oxalate arthritis and vasculitis in a patient with secondary oxalosis after jejunoileal bypass surgery. 38
18632590 2008
559
AA-amyloidosis can be transferred by peripheral blood monocytes. 38
18830411 2008
560
The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy. 38
18612836 2008
561
A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. 38
18496698 2008
562
Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? 38
18671471 2008
563
Treatment strategies for amyloid A amyloidosis. 38
18671466 2008
564
[Amyloidosis AA]. 38
18514052 2008
565
Characterization of the cheetah serum amyloid A1 gene: critical role and functional polymorphism of a cis-acting element. 38
18375929 2008
566
Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. 38
18541452 2008
567
Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. 38
18379834 2008
568
[Amyloidosis induced colonic stricture. The first symptom of myeloma multiplex. A case report]. 38
18547895 2008
569
[Treatment of amyloidosis]. 38
18552901 2008
570
Acceleration of murine AA amyloid deposition by bovine amyloid fibrils and tissue homogenates. 38
18484333 2008
571
Pathological study on amyloidosis in Cygnus olor (mute swan) and other waterfowl. 38
18592164 2008
572
Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. 38
18474855 2008
573
Lovastatin inhibits formation of AA amyloid. 38
18285405 2008
574
Diagnosis and management of autoinflammatory diseases in childhood. 38
18368292 2008
575
Gastrointestinal manifestations of amyloidosis. 38
18076735 2008
576
Renal amyloidosis in cattle with inflammatory diseases. 38
18312553 2008
577
Rapid induction of experimental AA amyloidosis in mink by intravenous injection of amyloid enhancing factor. 38
18266118 2008
578
Spontaneous perirenal hematoma with AA amyloidosis in a hemodialysis patient after unilateral nephrectomy. 38
18266124 2008
579
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. 38
18344807 2008
580
[Cardiac amyloidosis]. 9
18344065 2008
581
Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. 38
17951308 2008
582
Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. 38
18184882 2008
583
[AA amyloidosis: a little-known complication of chronic leg ulcer]. 38
18342093 2008
584
Secondary cutaneous nodular AA amyloidosis in a patient with primary Sjögren syndrome and celiac disease. 38
18431095 2008
585
AA amyloidosis associated with systemic lupus erythematosus: impact on clinical course and outcome. 38
17687556 2008
586
[AA amyloidosis due to renal cell carcinoma in a horseshoe kidney]. 38
18336144 2008
587
Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. 38
18369528 2008
588
Transthyretin amyloid goiter in a renal allograft recipient. 9
18369743 2008
589
[Systemic AA amyloidosis induced by benign neoplasms]. 38
18336138 2008
590
Which statin should be used together with colchicine? Clinical experience in three patients with nephrotic syndrome due to AA type amyloidosis. 38
17703308 2008
591
An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis. 38
18224416 2008
592
Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis. 38
19158968 2008
593
Another devastating complication of the Schnitzler syndrome: AA amyloidosis. 38
17941941 2008
594
[Management of immune suppression in systemic diseases affecting the kidney]. 38
18847427 2008
595
A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis. 38
18404797 2008
596
[A new treatment of renal disease in AA amyloidosis...and not only that?]. 38
18264913 2008
597
Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. 38
17714761 2007
598
Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. 38
17586002 2007
599
Analysis of SAA1 gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis. 38
17968686 2007
600
Systemic reactive (AA) amyloidosis in a patient with Glanzmann thrombasthenia. 38
17968693 2007
601
Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. 38
17611708 2007
602
[The spectrum of familial Mediterranean fever]. 38
17988598 2007
603
Eprodisate slows the progression of renal disease in patients with AA amyloidosis. 38
17876351 2007
604
Induction of murine AA amyloidosis by various homogeneous amyloid fibrils and amyloid-like synthetic peptides. 38
17953525 2007
605
Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. 38
17875183 2007
606
Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis. 38
17332981 2007
607
Amyloid A amyloidosis and systemic lupus erythematosus. 38
20477021 2007
608
Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. 38
17915620 2007
609
Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. 38
17762850 2007
610
Experimental AA amyloidosis in mice is inhibited by treatment with triptolide, a purified traditional Chinese medicine. 38
17630202 2007
611
Secondary amyloidosis in a needle phobic intra-venous drug user. 38
17701473 2007
612
Eprodisate in AA amyloidosis. 38
17855678 2007
613
Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. 38
17493579 2007
614
[A fatal case of pulmonary non-tuberculous mycobacteriosis with reactive AA amyloidosis]. 38
17763694 2007
615
[Renal manifestations in rheumatic diseases]. 38
17571244 2007
616
Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. 38
17591964 2007
617
Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. 38
17888205 2007
618
Typing of amyloidosis in renal biopsies: diagnostic pitfalls. 38
17550319 2007
619
Natural history and outcome in systemic AA amyloidosis. 38
17554117 2007
620
Eprodisate for the treatment of renal disease in AA amyloidosis. 38
17554116 2007
621
Secondary amyloidosis due to FMF. 38
17629039 2007
622
Inactivation of amyloid-enhancing factor (AEF): study on experimental murine AA amyloidosis. 38
17572844 2007
623
Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. 38
17577686 2007
624
The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study. 9
17103173 2007
625
[Familial Mediterranean fever: MEFV gene mutations and treatment]. 38
17473509 2007
626
Quiz page. Renal AA amyloidosis with vascular predominance, secondary to rheumatoid arthritis. 38
17687809</